Responses
Regular and young investigator award abstracts
Clinical trials in progress
320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
